DOCSLIB.ORG

WHO Drug Information Vol. 09, No. 4, 1995

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

WHO DRUG INFORMATION VOLUME 9 • NUMBER 4 • 1995 PROPOSED INN LIST 74 INTERNATIONAL NONPROPRIETARY N A M E S F O R P H A R M A C E U T I C A L SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA WHO DRUG INFORMATION WHO Drug Information provides an overview of topics relating to drug development and regulation that are of current relevance and importance, and includes the lists of proposed and recommended International Nonproprietary Names for Pharmaceutical Substances (INN). Its contents reflect, but do not present, WHO policies and activities and they embrace socioeconomic as well as technical matters. The objective is to bring issues that are of primary concern to drug regulators and pharmaceutical manufacturers to the attention of a wide audience of health professionals and policy-makers concerned with the rational use of drugs. In effect, the journal seeks to relate regulatory activity to therapeutic practice. It also aims to provide an open forum for debate. Invited contributions will portray a variety of viewpoints on matters of general policy with the aim of stimulating discussion not only in these columns but wherever relevant decisions on this subject have to be taken. WHO Drug Information is published 4 times a year and can be ordered from: Distribution and Sales, World Health Organization, 1211 Geneva 27, Switzerland. Annual subscription: Sw. fr. 66.— Airmail rate: Sw.fr. 78.— Price per copy: Sw.fr. 22.— © World Health Organization 1995 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation, in part or in toto, application should be made to: Chief, Office of Publications, World Health Organization, 1211 Geneva 27, Switzerland. The World Health Organization welcomes such applications. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Authors alone are responsible for views expressed in signed contributions. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature which are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. ISSN 1010-9609 Volume 9, Number 4, 1995 World Health Organization, Geneva WHO Drug Information Contents General Policy Topics Reports on Individual Drugs HIV: will effective treatment demand Acetylsalicylic acid: a protective effect against early diagnosis? 193 colorectal cancer 210 Nucleoside analogues: premonitory Update on AIDS experience in therapy of viral hepatitis 212 Amphotericin: a candidate for first-line 1. Antiretroviral drugs treatment of visceral leishmaniasis? 215 The cellular biology of HIV replication 196 Nuceloside analogues 196 The potential of combination therapy 197 General Information Other enzyme inhibitors 197 Polypharmacy, parenteral treatment, and The case for early intervention 198 blood-borne infection 217 Some ground rules for effective antiretroviral Increasing concerns about pneumococcal therapy 198 drug-resistance 217 2. Vaccines and genetic manipulation Regulatory Matters The immune response to HIV infection 201 Nifedipine: danger of short-acting formulations 220 Fundamental problems in vaccine Oral contraceptives and thromboembolism 221 development 202 Naftidrofuryl infusion withdrawn 222 Recombinant subunit vaccines: fresh doubts on feasibility 203 Attenuated vaccines: feasibility and risks 203 Essential Drugs A re-evaluation of strategy 204 WHO Model List (December 1995 revision) 223 New avenues of research 204 The potential of gene therapy 204 Proposed International Prospects for immune restitution 205 Rapid progress with nucleic acid vaccines 205 Nonproprietary Names: List 74 235 A globally-relevant option? 205 i World Health Organization, Geneva WHO Drug Information Volume 9, 1995: Index A E ACE inhibitors, (2) 62 Emergence of newly-resistant strains, (1) 2 renal failure, (1) 16 Enalapril, (1) 17 Acetylsalicylic acid, (1) 36, (2) 62 Erythromycin, (2) 75, (3) 143 colorectal cancer, (4) 210 Essential drugs, (2) 79 Acinetobacter, hospital-acquired infection, (1) 25 model list, (4) 235 AIDS update, (4) 196 Albendazole, (3) 135 Aminophylline, (2) 54 F Aminosalicylates, (3) 158 Fake drugs, (3) 127 Amphotericin, (4) 215 Fluconazole, cryptococcal meningitis, (1) 23 Antibiotic resistance, (1) 15 Antibiotics in eclipse, (1) 1 G Antibiotics, (3) 127 Gene therapy, HIV, (4) 204 Antimicrobial susceptibility tests, (3) 158 Glibenclamide, (2) 61 Antiretroviral therapy, (4) 198 Guidelines on defining the scope, (2) 77 Antistreptococcal vaccine, (1) 22 Azathioprine, (2) 68 H B Hepatitis B vaccination, (3) 146 Bacterial resistance, (1) 1 Herbal preparations, (3) 148 Bednets, malaria, (3) 151 HIV test, oral fluid, (1) 33 Bifidobacterium, (1) 14 HIV treatment, (4) 193 Budesonide, (2) 68 HIV vaccine development, (4) 202 Homoeopathy, (3) 149 C Hydroxyurea and sickle-cell disease, (1) 26 Captopril, (1) 16, (2) 63 Cefalosporins, (3) 142 I Chloraquine, (1) 39 Ibuprofen, (1) 37 Chlorpropamide, (2) 61 Indometacin, (1) 38 Ciclosporin, (2) 68 Influenza, vaccine, (3) 138 Clomifene, (3) 159 Informed consent in emergencies, (3) 154 Clozapine, (1) 34 INN lists, (2) 81, (3) 165, (4) 235 Community-acquired infections, (2) 43 Inosine pranobex, (4) 205 Contraceptives, spermicide, (3) 163 Insulin strength, (3) 163 Corticosteroids, (2) 68 Integrase inhibitors, (4) 197 Coumarin, (3) 159 Interferon alfa, (4) 205 Cyproterone acetate, (1) 30, (3) 162 Interferon gamma, (4) 205 Cysticidal drugs, (3) 135 lnterleukin-2, (4) 205 Iron chelation, beta-thalassaemia, (1) 28 D Iron-containing drugs, (3) 159 Deferiprone, (2) 57 Ivermectin, (3) 132, (3) 144 Defining the scope of the licensing procedure, (2) 77 K Dexamethasone, (3) 135 Kanamycin, (3) 142 Diabetes, non-insulin therapy, (2) 60 Didanosine, (4) 196 Diethylcarbamazine, (3) 132 L Diethylene glycol, (3) 127 Labelling, paediatric, (1) 32 Ditiocarb sodium, (4) 205 Lamivudine, (4) 196 Diuretics, (2) 70 Licence variations, (2) 73 DMPA, breast cancer, (1) 20 Licensing procedure, (2) 77 Drug resistance, (2) 44 Lymphatic filariasis, (3) 132 1 WHO Drug Information Volume 9, Index 1995 M S Macrolide antibiotics, (3) 162 Saccharomyces boulardii, (1) 15 Magnesium sulfate, (2) 63, (3) 130 Selegiline, (3) 160 Malaria, (3) 151 Silver nitrate, (3) 142 vaccine, (3) 135 Simvastatin, (3) 161 Measles vaccine, vitamin A, (3) 138 Socially-responsive development of Medical records, (3) 150 medicines, 11 (1) 1, III (2) 43 Medication errors, (3) 157 Spectinomycin, (3) 142 Mercaptopurine, (2) 68 Starting materials, pharmaceuticals, (3) 156 Metformin, (1) 30, (2) 61 Stavudine, (4) 196 Methotrexate, (1) 41, (2) 54, (2) 68 Streptokinase, (2) 62 Multidrug resistance, (1) 3 Sulfamethoxazole/trimethoprim, (3) 161 Myocardial infarction, (2) 62 Sulfasalazine, (1) 40, (2) 68 N Naftidrofuryl infusion, (4) 222 T Naltrexone, (1) 33 Tacrolimus, (3) 161 Natural medicines, (3) 147 Tamoxifen, (2) 72 Natural remedies, (3) 155 Tetracycline 1%, (3) 142 Nifedipine, (4) 220 Thiacetazone, (2) 55 Nucleoside analogues, (4) 196, 212 Tocolytics, (3) 160 Nucleic acid vaccines, (4) 205 Traditional eye medicines, (3) 152 Trimethoprim/sulfamethoxazole, (3) 161 O Triple-drug HIV regimens, (4) 197 Oral contraceptives, breast cancer, (1) 18 Tropical disease research, (3) 164 thromboembolism, (4) 221 Orphan drugs, (2) 72 u OTC advertising, (1) 10 Update on AIDS, (4) 196 P Use of essential drugs, (2) 79 Paediatric labelling, (1) 32 Pancreatic enzyme factor, (2) 58 V Pancreatins, (1) 30 Vaccine development, HIV, (4) 203 Penicillamine, (1) 40 new horizons, (2) 47 Penicillin, AIDS, (2) 66 Vaccine, antistreptococcal, (1) 22 Penicillin, neurosyphilis, (2) 66 hepatitis B, (3) 145 Pimozide, (1) 32 influenza, (3) 138 Pneumococcal drug-resistance, (4) 217 malaria, (3) 135 Poliomyelitis vaccine, (2) 59 measles, vitamin A, (3) 139 Polypharmacy, (4) 217 poliomyelitis, (2) 59 Povidone-iodine, (3) 142 rotavirus, (1) 14 Praziquantel, (3) 135 nucleic acid, (4) 205 Prednisolone, (1) 42, (2) 68 Vigabatrin, (2) 75 Product information, (2) 79 Vitamin A, (3) 141 Protease inhibitors, (4) 197 measles vaccine, (3) 139 Q Quality assurance, (3) 128 W Quinacrine, (1) 33 Warfarin, (3) 162 Quinolones, (3) 160 WHO Model List, (4) 223 R Reporting requirements, (2) 75 Z Resistant strains, (1) 3 Zalcitabine, (4) 196 Rheumatoid arthritis, (1) 35 Zidovudine, (4) 193, 196 Rotavirus vaccine, (1) 14 2 WHO Drug Information Vol. 9, No. 4, 1995 General Policy Topics HIV: will effective treatment widespread reticence exists (8). Throughout London as few as 12% of the total number of demand early diagnosis? pregnant women known to be HIV-positive by anonymous testing are currently consenting to The estimated number of persons with AIDS in the voluntary named testing, after being counselled to world increases inexorably year by year. Many do so in antenatal clinics (9). Similar reticence cases of the underlying HIV infection are now typifies attitudes within the USA (10). transmitted heterosexually and the proportion of women among those infected is rising. The risk of It has been suggested that,
Recommended publications
  • A Metabolomics Investigation Into the Effects of HIV Protease Inhibitors On

    A Metabolomics Investigation Into the Effects of HIV Protease Inhibitors On

    Molecular BioSystems View Article Online PAPER View Journal | View Issue A metabolomics investigation into the effects of HIV protease inhibitors on HPV16 E6 expressing Cite this: Mol. BioSyst., 2014, 10,398 cervical carcinoma cells† Dong-Hyun Kim,‡§a J. William Allwood,§¶a Rowan E. Moore,b Emma Marsden-Edwards,8b Warwick B. Dunn,¶a Yun Xu,a Lynne Hampson,c Ian N. Hampsonc and Royston Goodacre*ad Recently, it has been reported that anti-viral drugs, such as indinavir and lopinavir (originally targeted for HIV), also inhibit E6-mediated proteasomal degradation of mutant p53 in E6-transfected C33A cells. In order to understand more about the mode-of-action(s) of these drugs the metabolome of HPV16 E6 expressing cervical carcinoma cell lines was investigated using mass spectrometry (MS)-based metabolic profiling. The metabolite profiling of C33A parent and E6-transfected cells exposed to these two anti- viral drugs was performed by ultra performance liquid chromatography (UPLC)-MS and gas Creative Commons Attribution 3.0 Unported Licence. chromatography (GC)-time of flight (TOF)-MS. Using a combination of univariate and multivariate Received 23rd September 2013, analyses, these metabolic profiles were investigated for analytical and biological reproducibility and to Accepted 2nd January 2014 discover key metabolite differences elicited during anti-viral drug challenge. This approach revealed DOI: 10.1039/c3mb70423h both distinct and common effects of these two drugs on the metabolome of two different cell lines. Finally, intracellular drug levels were quantified, which suggested in the case of lopinavir that increased www.rsc.org/molecularbiosystems activity of membrane transporters may contribute to the drug sensitivity of HPV infected cells.
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
  • Stems for Nonproprietary Drug Names

    Stems for Nonproprietary Drug Names

    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
  • Downloaded from Survive Nursing | Survivenursing.Com V20110426

    Downloaded from Survive Nursing | Survivenursing.Com V20110426

    Generic Stem Stem Definition Examples -abine (see -arabine, -citabine) decitabine -ac Anti-inflammatory agents (acetic acid derivatives) bromfenac; dexpemedolac -acetam See -racetam -actide Synthetic corticotropins seractide -adol or -aldol- Analgesics (mixed opiate receptor agonists/ antagonists) tazadolene; spiradolene; levonantradol -adox Antibacterials (quinoline dioxide derivatives) carbadox -afenone Antiarrhythmics (propafenone derivatives) alprafenone; diprafenone -afil PDE5 inhibitors tadalafil -aj- Antiarrhythmics (ajmaline derivatives) lorajmine -aldrate Antacid aluminum salts magaldrate -algron Alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol Combined alpha and beta blockers labetalol; medroxalol -amivir (see -vir) -ampa Ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) -ampanel Ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) ; becampanel antagonists -ampator Ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) ; forampator modulators -andr- Androgens nandrolone -anib Angiogenesis inhibitors semaxanib -anserin Serotonin 5-HT2 receptor antagonists altanserin; tropanserin; adatanserin -antel Anthelmintics (undefined group) carbantel -antrone Antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine Antineoplastics (arabinofuranosyl derivatives) fazarabine; fludarabine aril-, -aril, -aril- Antiviral (arildone derivatives) pleconaril; arildone; fosarilate -arit Antirheumatics (lobenzarit type) lobenzarit; clobuzarit -arol
  • Vidarabine Phosphate (BANM, USAN, Rinnm) Stability

    Vidarabine Phosphate (BANM, USAN, Rinnm) Stability

    912 Antivirals Pharmacopoeias. In US. ◊ Reviews. Pharmacopoeias. In US. USP 31 (Valganciclovir Hydrochloride). A white to off-white 1. Freeman RB. Valganciclovir: oral prevention and treatment of USP 31 (Vidarabine). A white to off-white powder. Very slightly powder. Freely soluble in alcohol; practically insoluble in ace- cytomegalovirus in the immunocompromised host. Expert Opin soluble in water; slightly soluble in dimethylformamide. Store in tone or in ethyl acetate; slightly soluble in hexane; very soluble Pharmacother 2004; 5: 2007–16. airtight containers. in isopropyl alcohol. Store in airtight containers at a temperature 2. Cvetković RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immuno- of 25°, excursions permitted between 15° and 30°. compromised patients. Drugs 2005; 65: 859–78. Vidarabine Phosphate (BANM, USAN, rINNM) Stability. References. Administration in renal impairment. Doses of oral valgan- Ara-AMP; Arabinosyladenine Monophosphate; CI-808; Fosfato 1. Anaizi NH, et al. Stability of valganciclovir in an extemporane- ciclovir should be reduced in renal impairment according to cre- de vidarabina; Vidarabine 5′-Monophosphate; Vidarabine, Phos- ously compounded oral liquid. Am J Health-Syst Pharm 2002; atinine clearance (CC). Licensed product information recom- phate de; Vidarabini Phosphas. 9-β-D-Arabinofuranosyladenine 59: 1267–70. mends the following doses: 5′-(dihydrogen phosphate). 2. Henkin CC, et al. Stability of valganciclovir in extemporaneous- • CC 40 to 59 mL/minute: 450 mg twice daily for induction and Видарабина Фосфат ly compounded liquid formulations. Am J Health-Syst Pharm 2003; 60: 687–90. 450 mg daily for maintenance or prevention C10H14N5O7P = 347.2.
  • Report on the Deliberation Results August 17, 2016 Pharmaceutical

    Report on the Deliberation Results August 17, 2016 Pharmaceutical

    Report on the Deliberation Results August 17, 2016 Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau Ministry of Health, Labour and Welfare Brand Name Regroth Dental Kit 600 µg Regroth Dental Kit 1200 µg Non-proprietary Name Trafermin (Genetical Recombination) (JAN*) Applicant Kaken Pharmaceutical Co., Ltd. Date of Application October 1, 2015 Results of Deliberation In its meeting held on August 4, 2016, the First Committee on New Drugs concluded that the product may be approved and that this result should be presented to the Pharmaceutical Affairs Department of the Pharmaceutical Affairs and Food Sanitation Council. The re-examination period is 6 years. This product is not classified as a poisonous drug, a powerful drug, a biological product, or a specified biological product. Condition of Approval The applicant is required to develop and appropriately implement a risk management plan. *Japanese Accepted Name (modified INN) This English translation of this Japanese review report is intended to serve as reference material made available for the convenience of users. In the event of any inconsistency between the Japanese original and this English translation, the Japanese original shall take precedence. PMDA will not be responsible for any consequence resulting from the use of this reference English translation. Review Report July 15, 2016 Pharmaceuticals and Medical Devices Agency The following are the results of the review of the following pharmaceutical product submitted for marketing approval conducted by the Pharmaceuticals and Medical Devices Agency. Brand Name Regroth Dental Kit 600 µg Regroth Dental Kit 1200 µg Non-proprietary Name Trafermin (Genetical Recombination) Applicant Kaken Pharmaceutical Co., Ltd.
  • WO 2011/089216 Al

    WO 2011/089216 Al

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date t 28 July 2011 (28.07.2011) WO 2011/089216 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 47/48 (2006.01) C07K 1/13 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 1/1 07 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) Number: International Application DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/050821 HN, HR, HU, ID, J , IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 2 1 January 201 1 (21 .01 .201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1015 1465. 1 22 January 2010 (22.01 .2010) EP kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): AS- ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, CENDIS PHARMA AS [DK/DK]; Tuborg Boulevard TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 12, DK-2900 Hellerup (DK).
  • Customs Tariff - Schedule

    Customs Tariff - Schedule

    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
  • AHA/ASA Guideline

    AHA/ASA Guideline

    AHA/ASA Guideline lww Guidelines for the Early Management of Patients With Acute Ischemic Stroke A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. XXX Endorsed by the American Association of Neurological Surgeons and Congress of Neurological Surgeons Edward C. Jauch, MD, MS, FAHA, Chair; Jeffrey L. Saver, MD, FAHA, Vice Chair; Harold P. Adams, Jr, MD, FAHA; Askiel Bruno, MD, MS; J.J. (Buddy) Connors, MD; Bart M. Demaerschalk, MD, MSc; Pooja Khatri, MD, MSc, FAHA; Paul W. McMullan, Jr, MD, FAHA; Adnan I. Qureshi, MD, FAHA; Kenneth Rosenfield, MD, FAHA; Phillip A. Scott, MD, FAHA; Debbie R. Summers, RN, MSN, FAHA; David Z. Wang, DO, FAHA; Max Wintermark, MD; Howard Yonas, MD; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, and Council on Clinical Cardiology Background and Purpose—The authors present an overview of the current evidence and management recommendations for evaluation and treatment of adults with acute ischemic stroke. The intended audiences are prehospital care providers, physicians, allied health professionals, and hospital administrators responsible for the care of acute ischemic stroke patients within the first 48 hours from stroke onset. These guidelines supersede the prior 2007 guidelines and 2009 updates. Methods—Members of the writing committee were appointed by the American Stroke Association Stroke Council’s Scientific Statement Oversight Committee, representing various areas of medical expertise. Strict adherence to the American Heart Association conflict 2013 of interest policy was maintained throughout the consensus process.
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • WO 2011/103516 A2 25 August 2011 (25.08.2011) PCT

    WO 2011/103516 A2 25 August 2011 (25.08.2011) PCT

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau I (10) International Publication Number (43) International Publication Date WO 2011/103516 A2 25 August 2011 (25.08.2011) PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/536 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) Number: International Application CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US201 1/025558 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 18 February 20 11 (18.02.201 1) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/305,862 18 February 2010 (18.02.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): THE GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, TRUSTEES OF PRINCETON UNIVERSITY ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, [US/US]; P.O.